IL-17 cuts to the chase in colon cancer

Matthias Ernst; Tracy Putoczki

doi:10.1016/j.immuni.2014.12.004

IL-17 cuts to the chase in colon cancer

Immunity. 2014 Dec 18;41(6):880-2. doi: 10.1016/j.immuni.2014.12.004.

Authors

Matthias Ernst¹, Tracy Putoczki²

Affiliations

¹ The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville VIC 3052, Australia; Department of Medical Biology, University of Melbourne, Parkville VIC 3052, Australia. Electronic address: matthias.ernst@onjcri.org.au.
² The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville VIC 3052, Australia; Department of Medical Biology, University of Melbourne, Parkville VIC 3052, Australia. Electronic address: tracy.putoczki@wehi.edu.au.

PMID: 25526302
DOI: 10.1016/j.immuni.2014.12.004

Abstract

Although interleukin-17A (IL-17A) facilitates colon cancer development, its target cells remain elusive. In this issue of Immunity, Wang et al. (2014) now demonstrate that IL-17A receptors on the intestinal epithelium promote progression of APC mutant adenomas associated with IL-6 expression and that IL-17A confers chemotherapy resistance.

Publication types

Comment

MeSH terms

Animals
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Colonic Neoplasms / immunology*
Colorectal Neoplasms / immunology*
Enterocytes / physiology*
Humans
Receptors, Interleukin-17 / metabolism*

Substances

Il17ra protein, mouse
Receptors, Interleukin-17